Wall Street Zen Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to “Hold”

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts also recently weighed in on TLSI. Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Finally, Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.00.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $4.47 on Friday. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $7.95. The firm has a market capitalization of $223.77 million, a P/E ratio of -2.44 and a beta of 0.42. The stock has a 50 day moving average price of $5.36 and a 200 day moving average price of $5.36.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $13.20 million. As a group, sell-side analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of TLSI. Police & Firemen s Retirement System of New Jersey bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $29,000. JPMorgan Chase & Co. increased its stake in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $47,000. Invesco Ltd. bought a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at about $72,000. Finally, Abel Hall LLC purchased a new stake in TriSalus Life Sciences in the fourth quarter worth about $73,000. 2.58% of the stock is owned by institutional investors.

Key TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.